Melbourne, Australia:  Starpharma Holdings Limited (ASX: SPL; OCTQX: SPHRY) today released its Appendix 4C - Quarterly Cashflow report for the period ended 31 March 2012.

The cash balance at 31 March 2012 was $46.6m.  Total operating and investing cash outflow for the quarter was $2.2m.

Announcements during the quarter included:

• Receipt of final written agreement from the FDA on the design of the phase 3 clinical studies of VivaGel^® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.  The SPA is a binding declaration from the FDA that the proposed trial design, clinical endpoints and statistical analyses are acceptable for FDA approval once successfully completed.

• Commencement of the phase 3 VivaGel^® program for treatment of BV, which is being conducted in parallel with a phase 2 BV prevention of recurrence program.

• Release of animal data demonstrating that Starpharma’s dendrimer-docetaxel formulation was significantly more effective than leading cancer drug docetaxel (Taxotere^®) in a breast cancer model.

• The appointment of Peter Turvey, former CSL Executive Vice President Licensing, as a Non-Executive Director.

The phase 3 BV treatment trials are expected to be completed by the end of 2012.  The Company is in a strong cash position to be able to complete these activities in parallel with continuing to develop the range of product opportunities arising from its drug delivery and agrochemicals programs.

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report ( pdf file, 154kb)